

CONTACT US:

**The University of Chicago Medicine  
Comprehensive Cancer Center**

5841 S. Maryland Avenue  
Chicago, IL 60637

To refer a patient, call 1-800-824-2282.

[cancer.uchicago.edu](http://cancer.uchicago.edu)

 @UCCancerCenter  /UCCancerCenter

The University of Chicago Medicine  
*presents*

The Inaugural  
**ASH 2015 UPDATES:**  
PRACTICE CHANGING ABSTRACTS

Saturday, March 5, 2016

The University of Chicago Gleacher Center



THE UNIVERSITY OF  
**CHICAGO**  
MEDICINE



## DEAR ATTENDEES:

I welcome you to what promises to be an engaging and informative series of presentations about hematological malignancies. Today's discussions will continue the conversation from the ASH 2015 Annual Meeting and provide additional perspectives for your clinical and research practices.

The 30-member team in the University of Chicago Medicine Comprehensive Cancer Center hematopoiesis and hematological malignancies group takes an integrated, multidisciplinary approach toward researching the causes of blood cancers and applying those findings toward treating patients. Furthermore, we are the region's leader in early-phase clinical trials that have pioneered new and emerging therapies.

I encourage you to take the opportunity today to learn from our team and interface with your fellow physicians.

Sincerely,

*Michael R Bishop*



**Michael Bishop, MD**

Professor of Medicine

*Director, Hematopoietic Stem Cell  
Transplantation Program*

## TODAY'S AGENDA

- » 8:00-8:35 a.m.  
CAR-T Cell & Cellular Therapy: The Future is Now  
**Michael Bishop, MD**
- » 8:35-9:05 a.m.  
Clinical Highlights in Lymphoma  
**Sonali Smith, MD**
- » 9:05-9:35 a.m.  
Managing Patients with Myelodysplastic Syndromes  
**Olatoyosi Odenike, MD**
- » 9:35- 10:05 a.m.  
Update & Progress: Acute Leukemia  
**Wendy Stock, MD**  
10:05-10:35 a.m. BREAK
- » 10:35-11:05 a.m.  
Clinical Breakthroughs in CLL  
**Chadi Nabhan, MD, FACP**
- » 11:05-11:35 a.m.  
Updates on Non-Malignant Hematology  
**Kenneth Cohen, MD**
- » 11:35 a.m. - 12:05 p.m.  
Examining New Evidence & Advances in Multiple Myeloma  
**Andrzej Jakubowiak, MD, PhD**
- » 12:05- 12:35 p.m.  
Updates on Geriatric Hematology & Beyond  
**Andrew Artz, MD, MS**

## SPEAKER BIOGRAPHIES



### **Michael R. Bishop, MD**

*Professor of Medicine*

*Director, Hematopoietic Stem Cell Transplantation Program*

Michael R. Bishop, MD, specializes in the diagnosis and treatment of lymphomas and leukemias. In particular, he cares for patients with hematologic malignancies that have not responded to first-line treatments. An expert in hematopoietic stem cell transplantation (bone marrow transplantation), Dr. Bishop and his team are working to address the unique social, economic, physiological and biological issues that patients face while undergoing this treatment.

Dr. Bishop's research focuses on the prevention and treatment of relapse after stem cell transplantation. Relapse is the primary cause of treatment failure and death after stem cell transplantation. He has served as the primary investigator on studies designed to prevent and treat disease recurrence after transplantation. Specifically, he works on ways to enhance immune effects of the transplanted cells against cancer.

An active contributor to medical literature, Dr. Bishop has authored more than 150 peer-reviewed articles, in addition to more than 30 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including *Biology of Blood and Marrow Transplantation*.

Dr. Bishop is a dedicated mentor, teaching residents and fellows in classroom, clinical and research settings. Many of his past trainees hold leadership roles in medical oncology and immunology at academic medical centers or at the National Cancer Institute in Bethesda, Maryland.

Since 2001, Dr. Bishop has consistently been named one of the "Best Doctors in America" by Best Doctors, Inc. He previously served as a senior investigator and as the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.



### **Sonali M. Smith, MD**

*Associate Professor of Medicine*

*Director, Lymphoma Program*

Dr. Sonali M. Smith is an expert in the care and treatment of adults with all types of Hodgkin and non-Hodgkin lymphoma. She has a special interest in new agents for lymphoma, as well as stem cell transplantation and its role in improving the survival of patients with relapsed lymphomas.

An active researcher, Dr. Smith is involved in the development of promising agents for patients with non-Hodgkin and Hodgkin lymphoma. She is principal investigator on a number of innovative clinical trials. Many of the trials incorporate the collection of tumor and blood samples to study the effects of treatment on cancer cells through collaborative laboratories.



### **Olatooyosi Odenike, MD**

*Associate Professor of Medicine*

Dr. Olatooyosi Sobulo Odenike is an expert in the care of adults with leukemia, chronic myeloproliferative diseases, and myelodysplastic syndromes. She specializes in all types of treatment for these diseases, including blood and bone marrow stem cell transplant.

An active researcher, Dr. Odenike is involved in the development of novel therapeutic agents for the treatment of acute and chronic leukemias and chronic myeloproliferative diseases. The ultimate goal of her research is to improve treatment options for patients with these diseases. Dr. Odenike is the principal investigator on a number of clinical trials investigating molecularly targeted agents in this patient population. These clinical trials also integrate laboratory studies to evaluate the effect that these agents have on cancer cells.



### **Wendy Stock, MD**

*Anjali Seth Nayak Professor in Leukemia*

Wendy Stock, MD, is an authority in treating patients with all types of leukemia and myelodysplastic syndromes, including hematopoietic cell transplants. Her research efforts are directed to the design of clinical trials that tailor therapy to the individual patient. She recently led national trials for treatment of acute lymphoblastic leukemia (ALL) in adults and the University of Chicago's efforts to develop innovative trials for patients with advanced ALL and AML, including novel trials of allogeneic stem cell transplantation. Based on these insights, Dr. Stock and her colleagues have initiated a clinic for the specialized treatment of young adults with blood cancers.

Her laboratory has focused on the identification of new biological prognostic factors in specific subsets of leukemia and on the clinical significance of molecular detection and monitoring of subclinical disease (or minimal residual disease) using quantitative molecular methods.

Dr. Stock is a co-leader of the University of Chicago Cancer Research Center's Program in Hematopoiesis and Hematological Malignancies and is a core member of the Leukemia and Leukemia Correlative Sciences Committees in the Alliance, a NCI-sponsored clinical trials cooperative group. She is co-chair of the NCI national clinical trials network (NCTN) Leukemia Steering committee.



**Chadi Nabhan, MD, FACP**

*Associate Professor of Medicine  
Medical Director, Cancer Clinics*

Chadi Nabhan, MD, FACP, specializes in the diagnosis and management of hematologic malignancies (leukemias and lymphomas) as well as prostate cancer.

In his administrative role, Dr. Nabhan oversees clinical cancer services and operations at the University of Chicago Medicine. In this capacity, he supervises medical, surgical and radiation oncology, as well as radiology. He also coordinates interdisciplinary research efforts to advance patient care.

Dr. Nabhan has been as the primary investigator many clinical trials examining the effectiveness of new drugs and combination therapies in patients with hematologic malignancies and advanced prostate cancer. He is interested in investigating racial, ethnic, gender and age disparities in treatment approaches and outcomes for patients with lymphoid malignancies and CLL. In addition, Dr. Nabhan is working to develop targeted therapies for both disciplines exploring non-chemotherapeutic approaches.

In 2015, Dr. Nabhan was elected president of the Illinois Medical Oncology Society. A popular author and speaker, he has published more than 150 peer-reviewed articles, abstracts and book chapters. Some of his research work has been presented at national and international meetings. Dr. Nabhan serves on editorial boards of scientific journals, including *Leukemia Research and Treatment* and *American Journal of Blood*. He is also a reviewer for major medical journals such as *Annals of Internal Medicine*, *Cancer*, *Bone Marrow Transplantation*, *Annals of Oncology*, *European Journal of Hematology*, *British Journal of Hematology*, and *Leukemia/Lymphoma* amongst others.

Dr. Nabhan is a passionate teacher and a mentor to fellows, residents, and students and is an active participant in the development of their curriculum.



**Kenneth Cohen, MD**

*Assistant Professor of Medicine*

Kenneth Cohen, MD, specializes in treating adult patients with lymphoma and blood clotting disorders.

Dr. Cohen is the program director for the Section of Hematology/Oncology fellowship program. His research projects have studied how tumor blood vessels regulate immune cells. He has also studied factors that control blood cells that play a role in tumor blood vessel development.

Dr. Cohen has been an ad hoc reviewer for several medical journals including *Blood*, *Leukemia and Lymphoma*, and *Molecular Cancer Research*. He serves on the editorial board of *Analytical Cellular Pathology: Cellular Oncology*.



**Andrzej Jakubowiak, MD, PhD**

*Professor of Medicine  
Director, Myeloma Program*

Andrzej Jakubowiak, MD, PhD, is an internationally known expert on multiple myeloma, a cancer of the plasma cells in a patient's bone marrow. He works closely with the Multiple Myeloma Research Consortium (MMRC) to bring the latest treatments to the patient's bedside as quickly as possible.

Dr. Jakubowiak's primary research focus is in the development of new drugs for the treatment of multiple myeloma. He is currently the lead investigator on a number of multi-site clinical trials for patients who are newly diagnosed, have relapsed, or have refractory (resistant to treatment) disease. Dr. Jakubowiak has received research funding and several grants from the MMRC. He is also the recipient of many honors, including the Myeloma Center of the Year award by the MMRC in 2008 and 2010.

A frequently invited lecturer, Dr. Jakubowiak has presented his research findings at medical meetings around the world. He has published more than 50 peer-reviewed articles as well as 14 book chapters. Additionally, he serves as an ad hoc reviewer for several scientific journals, including the *Journal of Clinical Oncology*, *Blood* and *Leukemia and Lymphoma*.



**Andrew Artz, MD, MS**

*Associate Professor of Medicine*

Dr. Andrew Artz specializes in the care of patients with hematologic disorders and those undergoing stem cell transplantation, with a focus on older adults.

Dr. Artz's research interests include stem cell transplantation, leukemia, myelodysplastic syndromes (MDS) and anemia in the elderly. He holds a master's degree in health studies for clinical professionals from the University of Chicago.